SAB Biotherapeutics Ownership
| SABS Stock | USD 2.60 0.10 4.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. SAB Stock Ownership Analysis
About 21.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.13. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. SAB Biotherapeutics recorded a loss per share of 3.7. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 5th of January 2024. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company was founded in 2014 and is based in Sioux Falls, South Dakota. Sab Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. To find out more about SAB Biotherapeutics contact the company at 605 679 6980 or learn more at https://www.sabbiotherapeutics.com.Besides selling stocks to institutional investors, SAB Biotherapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different SAB Biotherapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align SAB Biotherapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
SAB Biotherapeutics Quarterly Liabilities And Stockholders Equity |
|
SAB Biotherapeutics Insider Trades History
About 21.0% of SAB Biotherapeutics are currently held by insiders. Unlike SAB Biotherapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against SAB Biotherapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of SAB Biotherapeutics' insider trades
SAB Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as SAB Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading SAB Biotherapeutics backward and forwards among themselves. SAB Biotherapeutics' institutional investor refers to the entity that pools money to purchase SAB Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2025-03-31 | 16.4 K | Kestra Advisory Services, Llc | 2025-03-31 | 11.9 K | Northern Trust Corp | 2025-03-31 | 11.4 K | Renaissance Technologies Corp | 2025-03-31 | 10 K | Advisor Group Holdings, Inc. | 2025-03-31 | 4.9 K | Sachetta Llc | 2025-03-31 | 4.1 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 449 | Mccormack Advisors International | 2025-03-31 | 217 | Gs Investment Inc | 2025-03-31 | 200 | Bvf Inc | 2025-03-31 | 917.8 K | Sessa Capital Im Lp | 2025-03-31 | 458.5 K |
SAB Biotherapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific SAB Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on SAB Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases SAB Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
SAB Biotherapeutics Outstanding Bonds
SAB Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. SAB Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most SAB bonds can be classified according to their maturity, which is the date when SAB Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| HYUELE 2375 19 JAN 31 Corp BondUS78392BAC19 | View | |
| HYUELE 15 19 JAN 26 Corp BondUS78392BAB36 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| US78390XAC56 Corp BondUS78390XAC56 | View | |
| SECBEN 65 Corp BondUS78397DAC20 | View | |
| SECBEN 7 Corp BondUS78397DAA63 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.